The in vitro pharmacology of LY IGlar (LY2963016): a new insulin glargine product

被引：0
|
作者：
Moyers, J. S. [1 ]
Kahl, S. D. [1 ]
Ruan, X. [1 ]
Zhang, C. [1 ]
Farmen, M. W. [1 ]
Michael, M. D. [1 ]
Owens, R. A. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
DIABETOLOGIA | 2015年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
519
引用
收藏
页码：S255 / S255
页数：1
相关论文
共 50 条
  • [31] Comparative Pharmacokinetics (PK) and Pharmacodynamics (PD) of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus® Insulin Glargine in Healthy Subjects
    Linnebjerg, Helle
    Lam, Eric Chen Quin
    Seger, Mary E.
    Coutant, David
    Chua, Laiyi
    Chong, Chew Lan
    Ferreira, Maria M.
    Soon, Danny
    Zhang, Xin
    [J]. DIABETES, 2014, 63 : A227 - A227
  • [32] COMPARATIVE PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF LY2963016 INSULIN GLARGINE AND EU-AND US-APPROVED VERSIONS OF LANTUS® INSULIN GLARGINE IN HEALTHY SUBJECTS
    Linnebjerg, H.
    Lam, E. C. Q.
    Seger, M.
    Coutant, D.
    Chua, L. Y.
    Chong, C. L.
    Ferreira, M.
    Soon, D.
    Zhang, X.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S264 - S265
  • [33] Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2
    Perez-Nieves, Magaly
    Pollom, Robyn K.
    Duan, Ran
    Kabul, Samaneh
    DeLozier, Amy M.
    Kaushik, Puneet
    Lllag, Liza
    [J]. GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2018, 7 (02): : 56 - 62
  • [34] Efficacy and Safety between Insulin Glargine Products (LY2963016 and Lantus®) in Patients with T2DM: The ELEMENT 5 Study
    Pollom, Robyn K.
    Lacaya, Lyndon B.
    Ilag, Liza L.
    [J]. DIABETES, 2017, 66 : A249 - A249
  • [35] Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trial
    Yan, Xiang
    Jiang, Shan
    Lou, Ying
    Zhou, Zhiguang
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (10): : 2226 - 2233
  • [36] Similar Efficacy and Safety of LY2963016 Insulin Glargine and Insulin Glargine (Lantus®) in Patients with T2D in Age Groups (< 65 Yrs,=65 Yrs)
    Pollom, Robyn K.
    Costigan, Timothy
    Lacaya, Lyndon B.
    Ilag, Liza L.
    Hollander, Priscilla A.
    [J]. DIABETES, 2016, 65 : A249 - A249
  • [37] Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trial
    Feng, Wenhuan
    Chen, Wei
    Jiang, Shan
    Du, Liying
    Zhu, Dalong
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (08): : 1786 - 1794
  • [38] Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine
    Liza L. Ilag
    Timothy M. Costigan
    Mark A. Deeg
    Robyn K. Pollom
    Curtis L. Chang
    Robert J. Konrad
    Melvin J. Prince
    [J]. Diabetes Therapy, 2017, 8 : 545 - 554
  • [39] Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine
    Ilag, Liza L.
    Costigan, Timothy M.
    Deeg, Mark A.
    Pollom, Robyn K.
    Chang, Curtis L.
    Konrad, Robert J.
    Prince, Melvin J.
    [J]. DIABETES THERAPY, 2017, 8 (03) : 545 - 554
  • [40] Duration of Action of 2 Insulin Glargine Products, LY2963016 and Lantus®, in Subjects with Type I Diabetes Mellitus (T1DM)
    Heise, Tim
    Zhang, Xin
    Lam, Eric Chen Quin
    Seger, Mary E.
    Coutant, David
    Chua, Laiyi
    Linnebjerg, Helle
    [J]. DIABETES, 2014, 63 : A228 - A228
12345